Phenotypes associated with this allele

• Allele Symbol: Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw
• Allele Name: transgene insertion 2A11, Kay-Uwe Wagner
• Allele ID: MGI:3849835
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cdkn2a^tm1Rdp/Cdkn2a^+ Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0	involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL	MGI:5521487
cn2	Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0	involves: 129P2/OlaHsd * FVB/N	MGI:5521486

Genotype
MGI:5521487

cn1

• Allelic Composition: Cdkn2a^tm1Rdp/Cdkn2a⁺; Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0; Tg(Pdx1-cre)6Tuv/0; Tg(tetO-MYC)36Bop/0
• Genetic Background: involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased pancreas tumor incidence ( J:197052 )

• mutants develop pancreatic tumors with a similar tumor latency as in mutants with wild-type Cdkn2a, however mice show an increase in the occurrence of more aggressive primary pancreatic ductal adenocarcinomas (PDACs) that quickly metastasized to the liver

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• mutants show an increase in the occurrence of more aggressive primary pancreatic ductal adenocarcinomas

• 77% of mice show invasive PDAC and 85% show poorly differentiated adenocarcinoma

increased metastatic potential ( J:197052 )

• primary pancreatic ductal adenocarcinomas quickly metastasize to the liver

• 67% incidence of metastases to the liver, 18% incidence to the lung, and 15% incidence to the thymus

endocrine/exocrine glands

increased pancreas tumor incidence ( J:197052 )

• mutants develop pancreatic tumors with a similar tumor latency as in mutants with wild-type Cdkn2a, however mice show an increase in the occurrence of more aggressive primary pancreatic ductal adenocarcinomas (PDACs) that quickly metastasized to the liver

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• mutants show an increase in the occurrence of more aggressive primary pancreatic ductal adenocarcinomas

• 77% of mice show invasive PDAC and 85% show poorly differentiated adenocarcinoma

mortality/aging

decreased tumor-free survival time ( J:197052 )

• due to pancreatic tumors

Genotype
MGI:5521486

cn2

• Allelic Composition: Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0; Tg(Pdx1-cre)6Tuv/0; Tg(tetO-MYC)36Bop/0
• Genetic Background: involves: 129P2/OlaHsd * FVB/N

mortality/aging

decreased tumor-free survival time ( J:197052 )

• mutants become moribund before they develop large tumors

neoplasm

increased pancreas tumor incidence ( J:197052 )

• mice develop pancreatic tumors as early as 14 days post partum

• all mice develop pancreatic neoplasms in less than 5 months

• 43% of mutants develop only ductal lesions, 46% of mutants have both ductal lesions and poorly differentiated carcinomas, and 11% of mutants exhibit only poorly differentiated adenocarcinomas

• 40-50 day old mutants with palpable pancreatic neoplasms treated with doxycycline for 7 days show cancer regression, however tumor-associated stroma does not remodel/regress

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinomas (PDACs) with sporadic metastasis to the liver

• 11% of mutants exhibit exclusively poorly differentiated adenocarcinomas that can metastasize to the liver, diaphragm, and lung

• 46% of mutants have both ductal lesions and poorly differentiated carcinomas, with a few mutants having moderately differentiated lesions that have an acinar-like appearance

increased pancreatic intraepithelial neoplasia incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinoma (PDACs) with sporadic metastasis to the liver

increased metastatic potential ( J:197052 )

• pancreatic ductal adenocarcinomas metastasize to the liver, diaphragm, and lung

endocrine/exocrine glands

increased pancreas tumor incidence ( J:197052 )

• mice develop pancreatic tumors as early as 14 days post partum

• all mice develop pancreatic neoplasms in less than 5 months

• 43% of mutants develop only ductal lesions, 46% of mutants have both ductal lesions and poorly differentiated carcinomas, and 11% of mutants exhibit only poorly differentiated adenocarcinomas

• 40-50 day old mutants with palpable pancreatic neoplasms treated with doxycycline for 7 days show cancer regression, however tumor-associated stroma does not remodel/regress

increased pancreatic ductal adenocarcinoma incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinomas (PDACs) with sporadic metastasis to the liver

• 11% of mutants exhibit exclusively poorly differentiated adenocarcinomas that can metastasize to the liver, diaphragm, and lung

• 46% of mutants have both ductal lesions and poorly differentiated carcinomas, with a few mutants having moderately differentiated lesions that have an acinar-like appearance

increased pancreatic intraepithelial neoplasia incidence ( J:197052 )

• 43% of mutants develop only ductal lesions that include pancreatic intraepithelial neoplasia (PanINs) and invasive pancreatic ductal adenocarcinoma (PDACs) with sporadic metastasis to the liver

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
pancreatic carcinoma		DOID:4905	OMIM:260350	J:197052